US2002123461A1PendingUtilityA1

Enhancement of GLP-2 activity

45
Assignee: ONTARIO INC 1149336Priority: Feb 1, 2001Filed: Feb 1, 2002Published: Sep 5, 2002
Est. expiryFeb 1, 2021(expired)· nominal 20-yr term from priority
Inventors:Daniel J. DruckerJulie Lovshin
A61K 38/26A61K 45/06
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical combination useful to treat, or to inhibit the onset of, a medical condition, disorder or disease for which treatment with GLP-2 is indicated, the combination comprising a GLP-2 activity enhancer and a GLP-1 activity inhibitor.  
     
     
         2 . A pharmaceutical combination according to  claim 1 , wherein said GLP-2 activity enhancer is a GLP-2 receptor agonist.  
     
     
         3 . A pharmaceutical combination according to  claim 2 , wherein said GLP-2 receptor agonist is human Gly2GLP-2.  
     
     
         4 . A pharmaceutical combination according to  claim 1 , wherein said GLP-1 activity inhibitor is a GLP-1 receptor antagonist.  
     
     
         5 . A pharmaceutical combination according to  claim 4 , wherein said GLP-1 receptor antagonist is exendin(9-39).  
     
     
         6 . A kit comprising a pharmaceutical combination as defined in  claim 1 , and instructions for the use thereof in treating or preventing the onset of said medical condition, disorder or disease.  
     
     
         7 . A method of medical treatment useful to treat or to inhibit the onset of a medical condition, disorder or disease for which treatment by GLP-2 is indicated, the method comprising the step of administering to the subject in need thereof a pharmaceutical combination as defined in  claim 1 .  
     
     
         8 . A method for treating or inhibiting the onset of a condition, disorder or disease of the gastrointestinal tract, comprising administering to a subject in need thereof a pharmaceutical combination as defined in  claim 1 .  
     
     
         9 . A method according to  claim 8 , wherein said subject is afflicted with or at risk of developing a condition selected from mucositis, IBD, Crohn's disease and small bowel syndrome.  
     
     
         10 . A method for treating a subject to suppress appetite, comprising administering to the subject an effective amount of a pharmaceutical combination according to  claim 1 .  
     
     
         11 . A method for treating a subject to suppress appetite according to  claim 10 , wherein said subject is an obese subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.